Lidocorit

Lidocaine, the active ingredient in Lidocorit, is a local anesthetic presented as an injectable solution for intravenous use. It provides rapid onset of local anesthesia and is also employed in the acute management of ventricular arrhythmias in adult patients. Its predictable pharmacokinetics and short half‑life make it useful for procedural sedation and cardiac rhythm control.

GNH USA supplies Lidocorit as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocorit (lidocaine) is used in clinical settings that require sodium‑channel blockade for pain control or cardiac rhythm stabilization. - Local anesthesia: provides rapid numbness for minor surgical or diagnostic procedures. - Ventricular arrhythmias: helps terminate or suppress life‑threatening ventricular tachycardia or fibrillation. - Acute pain management: offers short‑acting analgesia during invasive monitoring or catheterization.

Lidocorit may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: transient light‑headedness or vertigo. - Metallic taste: transient metallic sensation in the mouth. - Nausea: mild gastrointestinal upset. - Tingling or numbness: peripheral sensory changes. - Visual disturbances: blurred vision or diplopia. - Hypotension: mild drop in blood pressure.

Serious or Rare Side Effects: - Seizures: generalized convulsions, especially with high plasma levels. - Cardiac arrest: severe bradycardia or asystole. - Severe allergic reaction: anaphylaxis, urticaria, or angioedema. - Methemoglobinemia: cyanosis due to elevated methemoglobin. - Respiratory depression: marked reduction in breathing effort. - Persistent ventricular arrhythmia: paradoxical worsening of cardiac rhythm.

When using Lidocorit, clinicians should observe specific safety measures to minimize risks. - Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics or lidocaine. - Cardiac monitoring: continuously monitor ECG and blood pressure during intravenous administration. - Dose adjustment: reduce dose in patients with hepatic impairment or congestive heart failure. - Concomitant CNS depressants: use caution when combined with other agents that lower seizure threshold. - Pregnancy and lactation: avoid unless benefit outweighs potential risk, as safety data are limited. - Store below 25°C: keep in original container, protect from moisture and light.

Lidocorit can interact with other medicines, altering its plasma concentration or additive pharmacologic effects.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine levels and toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): raise plasma concentration, heightening risk of adverse effects. - CYP1A2 inducers (e.g., rifampin, carbamazepine): lower lidocaine concentrations, reducing efficacy.

Moderate Interactions (Monitor Closely): - Other sodium channel blockers (e.g., mexiletine, anti‑seizure drugs): additive cardiac effects. - Beta‑adrenergic blockers (e.g., propranolol): may enhance bradycardia. - Diuretics (e.g., furosemide): can potentiate hypotensive response. - Anticoagulants (e.g., warfarin): monitor for bleeding if invasive procedures are performed under lidocaine anesthesia.